Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. - Wikidata - wikimedia - TriplyDB

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

http://www.wikidata.org/entity/Q40327522

about

Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer?Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer Epithelial to Mesenchymal Transition in a Clinical Perspective Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer Cancer-associated fibroblasts in digestive tumors Epidermal growth factor signaling in transformed cells E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer EGFR-TKI resistance in NSCLC patients: mechanisms and strategies Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system Zeb1 links epithelial-mesenchymal transition and cellular senescence Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification In-depth analysis shows synergy between erlotinib and miR-34a Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma.Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.Intercellular transfer of proteins as identified by stable isotope labeling of amino acids in cell culture.Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer.Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors Up-regulation of sonic hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells Epigenetic Targeting of Transforming Growth Factor β Receptor II and Implications for Cancer Therapy CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.Cancer metastasis through the prism of epithelial-to-mesenchymal transition in circulating tumor cells.Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness.Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.Forkhead box L1 is frequently downregulated in gallbladder cancer and inhibits cell growth through apoptosis induction by mitochondrial dysfunction.Targeting the eicosanoid pathway in non-small-cell lung cancer.Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs.

P2860

Q24609974-58527B52-6576-41D9-AA49-CCF8902C091C Q24617121-8A20C6C9-66F8-4676-8D0D-F3279341CD35 Q24633879-C38ABEB1-E7D3-4C98-996A-E56C64691BC8 Q26741846-8A5BDBF3-DB99-4B61-8D04-387AE1AD673E Q26749110-ED05E23C-A971-457B-ACCA-4C8FBC4B6EAF Q26783554-EB037C77-29DF-40BF-AC3D-3527447E3B5B Q26798882-B7631186-B7E1-439C-AA36-826E25350AD4 Q26799987-E8DC4611-4284-423E-A62D-9B1D6E5DCE25 Q26864979-ED2837C6-68E5-4730-90C0-03B3A4D3BC89 Q26998615-91A4D8A7-79E1-4548-BB9C-7DDF14DE085F Q27022816-A857E74A-5A18-4BD2-97F0-33F8323460CA Q28084034-CE598657-6FC7-4844-A608-4CD04BFF47E0 Q28385103-2DF3EB99-7CDF-4E50-8F7C-502E474AC9A8 Q28387891-0847F6DE-AB66-4B0C-90A9-07A0E3754A87 Q28394310-A13277EE-F23C-4006-BD34-0FBB8E66B625 Q28484040-33178568-9420-4429-9EC8-F338B3FB7A69 Q28508357-1E35222E-6600-403A-8CDF-DD778F3F22DB Q28534577-1C7E1C4D-8CEB-4E14-87A3-B887B269805A Q28539851-CF39BFF1-8DBB-4B43-896E-DE028D911AF1 Q28544442-EA93E657-83C0-4D99-83F4-C60B0164FCA1 Q29616360-124757AD-D61C-477C-AD95-A5BEDED95708 Q30425201-CFD94433-1E6A-49AE-9598-7DEA8B2CA269 Q30434154-36171855-568A-4B5E-AF5E-1154D663F5C1 Q30434620-E2735905-4353-4034-95C3-738066B741A1 Q33265628-B9BDC0B3-425F-4AD5-8FC0-490E082A29A2 Q33267205-99B103CE-2CE0-4E6D-8345-6F067F99569A Q33391851-9F5082C6-49FD-4274-996B-2E28A5E02E0F Q33673605-DA4E2773-3FFB-4A3D-A069-C7616FE28438 Q33700204-35B560CD-CD6C-4789-AED5-24C11CCE299E Q33731197-5E6D3655-6005-4D71-B489-2F27D298E2A4 Q33732128-A467C249-2A8B-4B4D-B7E2-7AC6A26ACF27 Q33797788-5C06D77E-B53A-4DA7-AD31-065C7A2FCCD2 Q33802356-30F6186F-746D-4E64-877B-B6A5279ECA5B Q33808203-E8BE4BAE-656F-4259-9749-640DEBA0EF3F Q33869749-657ADE56-318D-41F1-A0D6-6C2AD4B297DE Q33869770-E92D5474-97A9-4DA4-A1F3-F2B96619B219 Q33880574-87EC3B0C-1E8B-44B0-98ED-DD09ADE657B8 Q33882630-86A59FF1-BC06-4B20-AC4A-FAB7F29C59DE Q33936807-4DAFF504-BC56-456E-84E3-243C9A6A5AE4 Q33939820-9D90D38E-8859-4ABF-9560-D43D377B3D4D

P2860

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

http://www.wikidata.org/entity/Q40327522

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Restoring E-cadherin expressio ...... ors in lung cancer cell lines.

@en

type

label

Restoring E-cadherin expressio ...... ors in lung cancer cell lines.

@en

prefLabel

Restoring E-cadherin expressio ...... ors in lung cancer cell lines.

@en

P1433

Q40327522-AA3E61E9-AC23-477F-BEEB-5522A93142D4

P1476

Q40327522-A8911609-31D2-4D84-9BD6-7B3AEC83A9C6

P2093

Q40327522-16099CF8-2DE4-4A73-9C21-7F8178AA70C8

Q40327522-336D66E3-1F10-494B-855B-5E49C5110082

Q40327522-357502F4-481B-434A-9B1D-CCFEE5C7FFE3

Q40327522-47B9DEBC-00EB-4B64-A400-C6A387AE5E24

Q40327522-618C6DDD-00E8-430F-82E7-E0E170718668

Q40327522-700FA2E6-B79E-4921-BCD6-F37AD5B68CC9

Q40327522-7E2C8252-2C4C-416B-A946-E5E15F2D87C7

Q40327522-7E318844-63C4-428F-BB9D-89A31D2E96FD

Q40327522-85E72732-FCD3-419A-937D-2A92C6FFC3CE

Q40327522-95A5C3BE-CF6F-4BBC-A789-8403DE86234C

P304

Q40327522-2D6EE10C-0E51-4A00-941B-3138B766207F

P31

Q40327522-91D93CEA-3137-4894-B2E6-88A17196A7BF

P356

Q40327522-AECCE952-DEFC-45DF-8CF5-2A3CC81D204E

P407

Q40327522-C1295A89-0D31-42BC-B5DB-5E33E3C38EA8

P433

Q40327522-8ED094CB-53E6-4E7C-8E1E-C649E770809C

P478

Q40327522-4D82B43B-D3E7-49C8-8D44-272F54671825

P50

Q40327522-3A4F0633-2786-4068-958A-A58688656CBF

P577

Q40327522-D94A5645-F36B-4DD5-99D2-6C7B99A9BB66

P5875

Q40327522-15269537-2794-4016-A490-03294EBDB895

P698

Q40327522-595BB470-9123-4EE7-AB7F-B49130D53675

P356

0008-5472.CAN-05-1988

P1433

Cancer Research

P1476

Restoring E-cadherin expressio ...... tors in lung cancer cell lines

@en

P2093

Adi F Gazdar

http://www.w3.org/2001/XMLSchema#string

Anna Baron

http://www.w3.org/2001/XMLSchema#string

Barbara Helfrich

http://www.w3.org/2001/XMLSchema#string

Christopher D Coldren

http://www.w3.org/2001/XMLSchema#string

Daniel C Chan

http://www.w3.org/2001/XMLSchema#string

Fred R Hirsch

http://www.w3.org/2001/XMLSchema#string

Harry A Drabkin

http://www.w3.org/2001/XMLSchema#string

John D Minna

http://www.w3.org/2001/XMLSchema#string

Karla Hedman

http://www.w3.org/2001/XMLSchema#string

Larisa Ravdel

http://www.w3.org/2001/XMLSchema#string

P304

944-950

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-05-1988

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Rafal Dziadziuszko

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7348783

http://www.w3.org/2001/XMLSchema#string

P698

16424029

http://www.w3.org/2001/XMLSchema#string